2022 年第 5 期 第 17 卷

安罗替尼单药与联合其他方案多线治疗老年消化道肿瘤患者的效果和安全性

Clinical efficacy and safety of anlotinib versus anlotinib combined with regimen on multi-line treatments of elderly patients with gastrointestinal tumors

作者：杨丽菲1路鹏霏2刘俊远1单莉1马玲1

英文作者：Yang Lifei1 Lu Pengfei2 Liu Junyuan1 Shan Li1 Ma Ling1

单位：1新疆医科大学附属肿瘤医院肺内科一病区，乌鲁木齐830000；2新疆医科大学第一附属医院肿瘤中心，乌鲁木齐830054

英文单位：1First Ward of Department of Pulmonary Medicine Cancer Hospital Affiliated of Xinjiang Medical University Urumqi 830000 China; 2Tumor Center the First Affiliated Hospital of Xinjiang Medical University Urumqi 830054 China

关键词：消化道肿瘤；安罗替尼；多线治疗

英文关键词：Gastrointestinaltumors;Anlotinib;Multi-linetherapy

• 摘要：

• 目的 观察安罗替尼单药与联合其他方案多线治疗老年消化道肿瘤患者的临床效果和安全性。方法 收集2018年6月至2019年5月新疆医科大学附属肿瘤医院收治的老年消化道肿瘤患者（年龄≥60岁）50例，均接受安罗替尼单药或安罗替尼联合其他方案多线治疗，安罗替尼用法为12 mg/次，1次/d，连续用药2周，休息1周，3周为1个周期。记录患者相关临床信息、治疗方案、不良反应发生情况、近期疗效与远期生存情况。结果 50例患者中有30例为安罗替尼单药治疗（单药治疗组），20例采用安罗替尼联合治疗（联合治疗组）。联合治疗组高血压、疲劳、肝功能损害、高三酰甘油血症和恶心呕吐发生率均明显高于单药治疗组，差异均有统计学意义（均P＜0.05）。治疗后，50例患者中部分缓解者占4.0%(2/50),稳定和进展者各占48.0%（24/50），客观缓解率和疾病控制率分别为4.0%（2/50）和52.0%（26/50）。截至2020年3月，50例患者随访1～20个月，中位随访时间为9.5个月，中位无进展生存期（PFS）为6.0个月，中位总生存期为10.8个月。联合治疗组PFS及总生存期均长于单药治疗组，差异均有统计学意义（均P＜0.05）。结论  安罗替尼联合其他方案多线治疗老年消化道肿瘤的远期疗效优于单药治疗，但治疗期间需严密观察药物不良反应。

• Objective  To observe the clinical efficacy and safety of anlotinib versus anlotinib combined with regimen on the treatment of elderly patients with gastrointestinal tumors. Methods Totally 50 elderly patients with gastrointestinal tumors (aged ≥60 years) admitted to Cancer Hospital Affiliated of Xinjiang Medical University from June 2018 to May 2019 were collected. The patients were treated with anlotinib alone or anlotinib combined with other regimens. The dosage of anlotinib was 12 mg/time, once a day, continuous medication for 2 weeks and stop for 1 week, 3 weeks as a cycle. The relevant clinical information, treatment plan and adverse reactions, short-term effects and long-term survival were recorded. Results  Among the 50 patients, 30 cases were treated with arotinib alone (single drug treatment group), and 20 cases were treated with arotinib combined with other regimens (combined treatment group). The incidences of hypertension, fatigue, liver function damage, hypertriglyceridemia, nausea and vomiting in combined treatment group were significantly higher than those in single drug treatment group(all P＜0.05). After treatment, no complete remission was found in 50 patients, 4.0%(2/50) for partial remission, 48.0%(24/50) each for stability and progress, and the objective remission rate and disease control rate were 4.0%(2/50) and 52.0%(26/50), respectively. By March 2020, 50 patients were follow-up for 1-20 months, the median follow-up time was 9.5 months, the median progression free survival (PFS) was 6.0 months, the median overall survival (OS) was 10.8 months, and no patients lost to follow-up. PFS and OS in the combined treatment group were longer than those in the single drug treatment group (all P＜0.05). Conclusion The long-term effect of anlotinib combined with multi-line treatment on elderly patients with gastrointestinal tumors is better than that of single drug treatment, but the adverse reactions should be closely observed during treatment.